Trials / Completed
CompletedNCT00441740
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine as First Line Treatment in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC). A Prospective , Multicenter, Randomized, Phase III Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 419 (actual)
- Sponsor
- Hellenic Oncology Research Group · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally advanced/metastatic NSCLC.
Detailed description
Cisplatin-based chemotherapy represented the backbone of treatment of advanced NSCLC. However, several trials comparing platinum versus non-platinum based chemotherapy regimens failed to demonstrate a statistically significant difference in terms of time to tumor progression or survival. Newer agents such as gemcitabine, docetaxel and vinorelbine have shown significant activity in the treatment of NSCLC. Gemcitabine/vinorelbine combination as first line treatment has demonstrated a response rate (RR) of 18-43% and a median overall survival (OS) of 9.8-13 months. Similarly, the gemcitabine/docetaxel combination has shown a RR 32-35% and a median OS of 9-12 months. Given their proven efficacy, the combination of these two doublets, would be interesting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinorelbine | Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles |
| DRUG | Gemcitabine | Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles |
| DRUG | Docetaxel | Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles |
| DRUG | Gemcitabine | Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-03-01
- Last updated
- 2008-10-31
Locations
9 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00441740. Inclusion in this directory is not an endorsement.